NT5E and breast carcinoma: Several studies reported that CD73 was up‐regulated in various cancers and higher CD73 level was generally associated with worse clinical outcomes,14, 15, 16, 17 but in other studies, increased CD73 expression was adversely considered as a favourable prognostic factor, such as epithelial ovarian carcinoma18 and breast cancer (stage I‐III).19